REGN) ? It's down huge for the year and it's a great company." A.O. Smith Corp …
The stock had its biggest gain on record ... Aimmune Therapeutics Inc. and Regeneron Pharmaceuticals Inc. are working together to develop a treatment for peanut allergies. Aimmune plans to release initial results from a late-stage trial of its …
Sectoral Asset Management Inc sold 29,981 shares as Regeneron Pharmaceuticals (REGN)’s stock rose 21.24%. The Sectoral Asset Management Inc holds 32,917 shares with $14.72M value, down from 62,898 last quarter. Regeneron
The stock decreased 0.31% or $1.03 during the last trading session, reaching $332.15. About 1.18 million shares traded …
As such, the analyst reiterates a Neutral rating on REGN stock without listing a …
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock on Tuesday traded at beginning with a price of $ 340.84 …
The rise in DBV's stock shows investors are looking more positively at DBV ... Aimmune also has a collaboration with Regeneron Pharmaceuticals Inc. and Sanofi S.A. to study AR101 with adjunctive Dupixent (dupilumab), with a Phase …
... on Regeneron Pharmaceuticals (REGN) MarketIntelligenceCenter.com’s patented trade-picking algorithms selected a Mar 16, 2018 $380 covered call for a net debit in the $362.68 area. That is also the break-even stock price for the …
That's a lot of positive regulatory news to pack into a single year, so it makes sense that Regeneron's stock was trading at a fresh 52-week high in the summer months. However, as you can probably guess, the good times didn't last. That …
so that Sanofi may sell a small percentage of the Regeneron common stock it owns to fund a portion of the cemiplimab and dupilumab development expansion. This waiver will allow Sanofi to sell in private transactions to Regeneron up to …